As of Jan 20
| -0.85 / -0.23%|
The 23 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 446.00, with a high estimate of 598.00 and a low estimate of 345.00. The median estimate represents a +23.01% increase from the last price of 362.56.
The current consensus among 27 polled investment analysts is to Hold stock in Regeneron Pharmaceuticals. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.